Additionally, PHF6mutAML and PHF6wt AML patients who received allo‐HSCT showed comparable OS (14.0 months vs. not reached, p = 0.085) and EFS (9.0 vs. 16.0 months; p = 0.192), suggesting that allo‐HSCT may at least partly overcome the poor prognosis related to PHF6 mutation (Figure 2C,D). Here, PHF6 is linked to acute myeloid leukemia.